NEW YORK (GenomeWeb) – GeneNews today reported a 44-fold year-over-year increase in its second quarter revenues.

The Toronto-based molecular diagnostics company reported that for the three months ended June 30, its revenues rose to C$441,111 (US$592,137) from C$10,019 in the year-ago period. Royalty revenues made up all of GeneNews' revenues for the recently completed quarter and were up from C$7,472 a year ago. The firm had no test revenues for Q2 2014, compared to C$2,547 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.